BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
Yeah, so I was so excited to see the results of this study, especially after last year, we saw the really exciting results of EV plus PEMBRO in the metastatic setting. And then we saw the Checkmate 901 data, where when nivolumab was added to GEMSYS, it did better than just GEMSYS alone. And that just kind of set the stage for the perioperative trials that are
0
💬
0
Comments
Log in to comment.
There are no comments yet.